VivaMed BioPharma, a clinical-stage pharmaceutical company harnessing AI to discover and advance repurposed therapies, has announced a strategic partnership with Syngene International, a global contract research, development, and manufacturing powerhouse.
The collaboration aims to accelerate VivaMed’s validation infrastructure and bring AI-derived drug candidates closer to clinical and commercial readiness.
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities, creating a seamless pathway from AI discovery to experimental validation.
“AI-driven discovery must be matched with rigorous experimental execution,” said Kendric Speagle, CEO of VivaMed. “Our partnership with Syngene strengthens our validation engine and ensures that our most promising programs are developed with the scientific depth and operational discipline required for pharmaceutical collaboration.”
VivaMed’s model focuses on three core areas:
1. AI-Powered Discovery: Leveraging a proprietary AI engine and a global network of co-scientists to uncover multi-omic datasets, biomarkers, and high-potential repurposing opportunities.
2. Rigorous Validation: Syngene will support in-vitro and in-vivo pharmacology studies, biomarker confirmation, assay development, mechanistic pathway interrogation, and preclinical development, ensuring reproducibility, IP protection, and regulatory readiness.
3. Strategic Commercialization: Programs are aligned with pharmaceutical partner priorities, using 505(b)(2) pathways and biomarker-driven strategies to create de-risked, scalable development opportunities.
“We are very excited to collaborate with an innovative company like VivaMed,” said Kenneth Barr, Senior Vice President and Head of Strategic Collaborations at Syngene. “This partnership strengthens our ability to apply a scaled drug development model to repurposed assets, translating high-throughput research into credible therapeutic candidates for the ultimate benefit of patients.”
Barr emphasized that combining AI platforms with Syngene’s end-to-end capabilities could significantly shorten development timelines and accelerate repurposed medicines to market.
The partnership reflects VivaMed’s broader mission to create a globally integrated, AI-enabled drug development network. By linking computational prioritization with proven CRO validation capabilities, VivaMed is designing infrastructure capable of generating repeatable, partnership-ready outputs.
“Our objective is to deliver assets that are not only scientifically compelling, but operationally aligned with modern pharmaceutical development,” added John Shufeldt, President and CMO of VivaMed. “Strategic partnerships like this one create a scalable foundation for continued collaboration.”
